|
Indian Pediatr 2018;55:222-224 |
|
Carnitine Deficiency in Chinese Children
with Epilepsy on Valproate Monotherapy
|
Li Qiliang 1,
Song Wenqi1 and
Jin Hong2
From Departments of 1Medical Laboratory
and 2Neurology, Beijing Children’s Hospital, Capital Medical
University,
National Center for Children’s Health, Beijing, China.
Correspondence to: Dr Song Wenqi, Department of
Medical Laboratory, Beijing Children’s Hospital, Capital Medical
University, National Center for Children’s Health, Beijing, 100045,
China.
Email: [email protected]
Received: September 22, 2016;
Initial review: February 08, 2017;
Accepted: January 03, 2018.
|
Objective: To explore the incidence and
independent risk-factors of secondary carnitine deficiency in Chinese
children with epilepsy on valproate monotherapy. Methods:
The free carnitine and acylcarnitines levels in 299 children with
epilepsy on valproate monotherapy between June 2014 and September 2015
were compared with age- and sex-matched 299 healthy controls.
Results: Children with valproate monotherapy had lower free
carnitine levels [23.86 (10.60) µmol/L] than the controls [36.37 (9.37)
µmol/L] (P<0.01). Most acylcarnitines were significantly lower in
children with valproate monotherapy than controls. 63 children
(21.1%) with epilepsy had carnitine deficiency; 54 were asymptomatic.
Female gender (OR 2.1), high alanine aminotransferase levels (OR 1.0)
and long duration of VPA treatment (1-12 mo) (OR 1.9) were independent
risk factors for secondary carnitine deficiency induced by VPA.
Conclusions: Carnitine deficiency with valproate is more likely in
females, those with transaminitis, and those receiving the drug for 1-12
months.
Keywords: Acylcarnitine, Adverse-effects, Outcome,
Toxicity.
|
V alproate (VPA), the most widely prescribed
antiepileptic drug (AED) worldwide [1] has a chemical structure similar
to short chain fatty acids [2]. Carnitine is an amino acid derivative,
which plays a very important role in the oxidation of fatty acids [3,4].
Carnitine deficiency is a metabolic state in which free carnitine in
plasma is less than 20 µmol/L [5]. The effect of VPA on carnitine levels
has been debated since long (6-11). In order to explore the incidence
and independent risk factors of carnitine deficiency in children
with VPA monotherapy, we measured the levels of free carnitine and
acylcarnitines in Chinese children receiving VPA monotherapy and
healthy controls.
Methods
Children with epilepsy (n=299) were enrolled
at Beijing Children’s hospital between June 2014 and September 2015.
Inclusion criteria for patients were age 1 to 17 years; receiving
valproate monotherapy; and treated with VPA for more than 1 month.
Exclusion criteria for patients were: those on special dietary therapies
such as ketogenic diet; with carnitine supplements; receiving steroid
drugs; a diagnosis of progressive degenerative, musculoskeletal or
metabolic diseases; and inhibition of intake of a varied diet. Age- and
sex-matched 299 healthy subjects were recruited at the same hospital
within the same period. Exclusion criteria for controls included those
with carnitine-modifying healthcare products or only vegetarian diet.
The protocol was approved by the Ethical Committee of
Beijing Children’s hospital. Written informed consents were obtained
from the participants and their guardians. Dry blood spots samples were
collected. Free carnitine and acylcarnitines were analyzed by LC-MS/MS
(AB SCIEX, United States).
Statistical analysis was carried out using SPSS 13.0
(Armonk, New York, USA). The data of free carnitine and acylcarnitines
between patients and controls were analyzed using independent-samples t
test. Logistic regression was used to evaluate the relevant factors to
carnitine deficiency. The difference was considered statistically
significant at P<0.05.
Results
The mean (SD) durations of VPA treatment in cases
were 2.0 (1.1) years, the VPA dose was 410.7 (136.1) mg/day, and the VPA
concentration was 62.5 (20.1) mg/L. The mean (SD) levels of ALT and AST
in the children with epilepsy before valproate treatment were 15.93
(8.99) IU/L and 27.10 (6.58) IU/L, respectively. The mean (SD) levels of
ALT and AST in controls were 16.10 (9.48) IU/L and 26.61 (7.48) IU/L,
respectively. The mean (SD) levels were ALT [15.72 (10.63) IU/L], AST
[27.15 (14.36) IU/L], Urea [4.5 (1.6) mmol/L], and Creatinine [36.8
(16.5) µmol/L] of the children with epilepsy after VPA
monotherapy.
The cases presented significantly lower free
carnitine levels [23.86 (10.60) µmol/L] than controls [36.37 (9.37)
µmol/L] (P<0.01). Most acylcarnitines were changed in patients
with VPA treatment (Web Table I). The short chain
acylcarnitines (except for C5DC) were significantly lower in the
patients than in the control group. The ratio of short-chain
acylcarnitines to free carnitine were significantly higher (P<0.01)
in the patients. The ratio of medium chain acylcarnitine to free
carnitine was not significant in the patients with VPA treatment and
controls (P>0.05). The ratio of long-chain acylcarnitines to free
carnitine was significantly higher (P<0.01) in the patients.
63 (21.1%) children with epilepsy were found to have
carnitine deficiency; 54 of these were asymptomatic. Manifestations of
carnitine deficiency observed in the remaining nine (8 females) included
reversible weakness, hypotonia, and mental retardation, which were
possibly related to lack of energy supply induced by carnitine
deficiency.
The alternative risk factors in the multivariate
logistic regression analysis included age, gender, durations of VPA
treatment, urea concentration, creatinine concentration, ALT
concentration, AST concentration and VPA trough concentration. Female
gender, higher level of ALT serum concentration and the duration of VPA
treatment (>1month, <12months) were the independent risk factors
to secondary carnitine deficiency induced by VPA (Table I).
TABLE I Independent Risk-factors of Carnitine Deficiency Associated With Valproate USE
Variable
|
Odds Ratio (95%) |
Age £3y |
1.9 (0.87-4.35) |
#Female gender |
2.1 (1.17-3.84) |
$#Duration of treatment
|
1.9 (1.02-3.47) |
*High VPA levels
|
1.0 (0.99-1.02) |
#High ALT
|
1.0 (1.00-1.06) |
High AST
|
1.0 (0.98-1.02) |
High Urea
|
1.1 (0.95-1.38) |
Higher Creatinine
|
1.0 (0.99-1.03) |
AST: aspartate aminotransferase; ALT: alanine
aminotransferase; #P<0.05; *Valproate serum trough
concentrations; $Duration of VPA treatment (>1 mo and <12 mo). |
Discussion
In this study, we found low free carnitine
concentration in patients with VPA monotherapy compared with controls;
63 children with epilepsy (21.1%) were found to suffer carnitine
deficiency induced by VPA. In addition, we found the most acylcarnitines
were significantly lower in the children with valproate
monotherapy.
Our study was consistent with some studies which
reported that VPA could induce the lower levels of free carnitines and
acylcarnitines [9-11]. However, the study was limited by small sample
size and the absence of baseline carnitine levels in epileptic children
before VPA treatment, so we compared the levels of free carnitine and
acylcarnitines between patients after VPA treatment and controls.
The possible reasons for differences could be as
follow: (i) female patients prefer vegetarian diet not animal
product in which L-carnitine is abundant; (ii) VPA was catalyzed
to 4-pentenoic acid Valproate (4-ene VPA) which could reduce
hepatotoxicity and reduced
of synthesis of carnitines [12,13]; and (iii) the period of VPA
treatment between 1 month and 12 months was key period that the
important organs such as kidney and liver adapted to VPA treatment. The
stimulation of VPA on kidney and liver possibly effected carnitine
reabsorption and liver synthesis.
Although some patients suffering from carnitine
deficiency were asymptomatic or had mild symptoms, some studies showed
that long term carnitine deficient status could cause some serious
consequences, even life-threatening complications such as
encephalopathy. Therefore, diagnosis and treatment of carnitine
deficiency without delay might be useful for patients [5,14-15]. We
suggest that free carnitine and acylcarnitines of high-risk patients
should be screened. In addition, we speculate that patients with
carnitine deficiency associated with valproate might be benefit from L-carnitine
supplementation. However, further longitudinal studies are needed to
confirm these findings.
Contributors: LQL: initiated the project and
wrote the paper; SWQ: is the guarantor and carried out the study; JH:
collected the clinical data. All authors contributed to the design and
interpretation of the study and to further drafts.
Funding: Special Program for Capital
Clinical Research of the Beijing municipal commission of science and
technology and WU JIE PING medical foundation, China (Grant No.
Z121107005112008).
Competing interests: None stated.
What This Study Adds?
• Children
with epilepsy receiving VPA had low carnitine levels,
especially females, those with transaminitis and with the
duration of VPA treatment being 1month-12months.
|
References
1. Nakashima H, Oniki K, Nishimura M, Ogusu N,
Shimomasuda M, Ono T, et al. Determination of the optimal
concentration of valproic acid in patients with epilepsy: A population
pharmacokinetic-pharmaco-dynamic analysis. PLoS One. 2015; 10:e0141266.
2. Silva MF, Aires CC, Luis PB, Ruiter JP, IJlst L,
Duran M, et al. Valproic acid metabolism and its effects on
mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis.
2008;31:205-16.
3. Lheureux PE, Hantson P. Carnitine in the treatment
of valproic acid-induced toxicity. Clin Toxicol (Phila). 2009;47:101-11.
4. El-Hattab AW, Scaglia F. Disorders of carnitine
biosynthesis and transport. Mol Genet Metab. 2015;116:107-12.
5. De Vivo DC, Bohan TP, Coulter DL, Dreifuss FE,
Greenwood RS, Nordli DR Jr, et al. L-carnitine supplementation in
childhood epilepsy: current perspectives. Epilepsia. 1998;39:1216-25.
6. Hirose S, Mitsudome A, Yasumoto S, Ogawa A, Muta
Y, Tomoda Y. Valproate therapy does not deplete carnitine levels in
otherwise healthy children. Pediatrics. 1998;101:E9.
7. Fung EL, Tang NL, Ho CS, Lam CW, Fok TF. Carnitine
level in Chinese epileptic patients taking sodium valproate. Pediatr
Neurol. 2003;28:24-7.
8. Cansu A, Serdaroglu A, Biberoglu G, Tumer L,
Hirfanoglu TL, Ezgu FS, et al. Analysis of acylcarnitine levels
by tandem mass spectrometry in epileptic children receiving valproate
and oxcarbazepine. Epileptic Disord. 2011;13:394-400.
9. Fukuda M, Kawabe M, Takehara M, Iwano S, Kuwabara
K, Kikuchi C, et al. Carnitine deficiency: Risk factors and
incidence in children with epilepsy. Brain Dev. 2015;37:790-6.
10. Beghi E, Bizzi A, Codegoni AM, Trevisan D, Torri
W. Valproate, carnitine metabolism, and biochemical indicators of liver
function. Collaborative Group for the Study of Epilepsy. Epilepsia.
1990;31:346-52.
11. Moreno FA, Macey H, Schreiber B. Carnitine levels
in valproic acid-treated psychiatric patients: a cross-sectional study.
J Clin Psychiatry. 2005;66:555-8.
12. Kutlu O, Cansu A, Karagüzel E, Gürgen SG, Koç O,
Gür M, et al. Effect of valproic acid treatment on penile
struc-ture in prepubertal rats. Epilepsy Res. 2012;99:306-11.
13. Surendradoss J, Chang TK, Abbott FS. Assessment
of the role of in situ generated (E)-2, 4-diene-valproic acid in the
toxicity of valproic acid and (E)-2-ene-valproic acid in
sandwich-cultured rat hepatocytes. Toxicol Appl Pharmacol.
2012;264:413-22.
14. Nakamura M, Nagamine T. The effect of
carnitine supplementation on hyperammonemia and carnitine deficiency
treated with valproic acid in a psychiatric setting. Innov Clin Neurosci.
2015;12:18-24.
15. Mock CM, Schwetschenau KH. Levocarnitine for valproic-acid-induced
hyperammonemic encephalopathy. Am J Health Syst Pharm. 2012;69:35-9.
|
|
|
|